alanine has been researched along with brivanib in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (8.45) | 29.6817 |
| 2010's | 62 (87.32) | 24.3611 |
| 2020's | 3 (4.23) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; Chao, S; D'Arienzo, C; Derbin, G; Fargnoli, J; Fura, A; Hunt, JT; Jeyaseelan, R; Kamath, A; Kim, SH; Kukral, D; Leavitt, K; Leith, L; Lombardo, LJ; Marathe, P; Mathur, A; Mortillo, S; Qian, L; Vyas, V; Wautlet, B; Wei, D; Wu, LI; Zhang, YZ; Zheng, X | 1 |
| Ayers, M; Fargnoli, J; Lewin, A; Platero, JS; Wu, Q | 1 |
| Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; D'Arienzo, C; Derbin, G; Fan, J; Fargnoli, J; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Marathe, P; Mortillo, S; Qian, L; Robl, JA; Shi, Z; Wautlet, BS; Wei, D; Wu, L; Zhang, Y; Zheng, X | 1 |
| He, BL; Kleintop, B; Raglione, T; Shi, Y | 1 |
| Ayers, M; Byron, S; Chow, P; Chung, A; Fargnoli, J; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Pollock, P; Soo, KC; Thng, CH; Tran, E | 1 |
| Bhide, R; D'Arienzo, C; Fargnoli, J; Kamath, AV; Marathe, PH; Zhang, Y | 1 |
| Andre, F; Fraser Symmans, W; Hortobagyi, GN; Lazar, V; Pusztai, L; Qi, Y; Shiang, CY; Wang, B; Wang, J | 1 |
| Barrish, JC; Bhide, RS; Cai, ZW; Fargnoli, J; Galbraith, S; Henley, BJ; Hunt, JT; Jeyaseelan, R; Krishnan, B; Kukral, D; Lewin, AC; Lombardo, LJ; Malone, H; Mortillo, S; Wautlet, BS | 1 |
| Fargnoli, J; Jordan, VC; Kim, HR; Klein-Szanto, AJ; Li, T; Oseni, S; Patel, RR; Pyle, JR; Ross, EA; Sengupta, S; Zhu, F | 1 |
| Fischer, BS; Gan, J; Ganapathi, R; Gong, J; Iyer, R; Masson, E; Mekhail, T; Patricia, D; Pursley, J; Williams, D | 1 |
| Dempke, WC; Zippel, R | 1 |
| de Braud, F; Feltquate, DM; Galbraith, S; Goss, G; Jayson, GC; Jonker, DJ; Kantor, J; Kollia, G; McArthur, GA; Mokliatchouk, O; Nuyten, DSA; Rosen, LS; Rustin, G; Sawyer, MB; Sweeney, CJ; Syed, S; Velasquez, L; Wilding, G | 1 |
| Allentoff, A; Arora, V; Caceres-Cortes, J; Christopher, LJ; Gan, J; Gong, J; Iyer, RA; Lago, M; Masson, E; Pursley, J; Tran, SB; Williams, D | 1 |
| Baudelet, C; Finn, RS; Harris, R; Ismail, F; Karwal, M; Kim, JS; Li, RK; Park, JW; Raoul, JL; Thomas, M; Walters, I | 1 |
| Diaz-Padilla, I; Siu, LL | 1 |
| Chemidlin, J; Fischer, B; Hurwitz, H; Kollia, G; LoRusso, P; Masson, E; Pilat, MJ; Shapiro, GI; Syed, S | 1 |
| Allen, E; Hanahan, D; Walters, IB | 1 |
| Buter, J; Chemidlin, J; El-Khoueiry, A; Feltquate, D; Ford, S; Galbraith, S; Garrett, CR; Hayes, W; Kollia, G; LoRusso, P; Major, P; Marshall, J; Mokliatchouk, O; Nuyten, DS; Rocha-Lima, CM; Siu, LL; Syed, S; Velasquez, L | 1 |
| Clemens, PL; Dhar, A; Kollia, G; Lathers, D; Masson, E; Syed, S; Walters, I | 1 |
| Phan, A; Yao, JC | 1 |
| Kudo, M | 1 |
| Abbas, A; Jones, H; Kingston, GT; Zurek, A | 1 |
| Gan, J; Gong, J; Iyer, RA | 1 |
| Badawy, S; Derbin, G; Hussain, M; Miller, S; Zhao, F | 1 |
| Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I | 1 |
| Llovet, JM; Villanueva, A | 1 |
| Badawy, S; Bindra, DS; Comezoglu, SN; Doyle, ML; Narang, AS; Varia, S; Yamniuk, AP; Zhang, L | 1 |
| Badawy, SI; LaMarche, K; Narang, AS; Subramanian, G; Varia, SA | 1 |
| Gan, J; Gong, J; Humphreys, WG; Iyer, RA; Jemal, M; Masson, E; Pursley, J; Syed, S; Williams, D; Xia, YQ | 1 |
| Chou, T; Finn, RS | 1 |
| Chang, AY; Wang, M | 1 |
| Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Forestieri, D; Giavazzi, R; Licandro, SA; Richter, P; Taraboletti, G; Zucchetti, M | 1 |
| Cho, BC; Kim, HR; Lim, SM; Shim, HS; Soo, RA | 1 |
| Charpentier, D; Couture, F; Haydon, A; Jefford, M; Jonker, DJ; Karapetis, CS; Liauw, W; Magoski, NM; Moore, MJ; Nott, LM; O'Callaghan, CJ; Price, TJ; Ringash, J; Sawyer, MB; Shapiro, JD; Siddiqui, J; Simes, J; Siu, LL; Tu, D; Walters, I; Zalcberg, JR | 1 |
| Castillo Ferrando, JR; El-Khoueiry, A; Fischer, BS; Kollia, G; Krishnamurthi, SS; Masson, E; Posey, JA; Syed, S; Walters, I | 1 |
| Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L | 1 |
| Kelley, RK | 1 |
| Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I | 1 |
| Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC | 1 |
| Choi, D; Hwang, JH; Im, GH; Kim, JH; Lee, JH; Namgung, M; Song, KD; Yang, J; Yoon, S | 1 |
| Alcindor, T; Au, HJ; Easaw, JC; El-Tahche, F; Jeffery, M; Jonker, DJ; Kotb, R; Moore, MJ; Ng, S; O'Callaghan, CJ; Ringash, J; Sabesan, S; Salim, M; Shannon, J; Shapiro, JD; Siu, LL; Strickland, A; Tu, D; Walters, I; Zalcberg, JR | 1 |
| Hsieh, YC; Huang, YT; Hwang, LH; Kuo, YJ; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Yang, YY | 1 |
| Banini, BA; Kim, TH; Mikhail, DS; Moser, CD; Nakamura, I; Roberts, LR; Shaleh, HM; Thornburgh, SR; Walters, I; Yang, JD; Zakharia, K | 1 |
| Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P | 1 |
| Badawy, SI; Desai, S; Gokhale, M; LaMarche, KR; Lin, J; Narang, AS; Nesarikar, VV; Subramanian, GA | 1 |
| Choi, D; Im, GH; Kim, JH; Lee, JH; Lee, WJ; Song, KD; Yang, J | 1 |
| Blanc, JF; Dela Cruz, C; Finn, RS; Han, G; Kudo, M; Lee, JH; Lin, SM; Lu, L; Poon, RT; Poulart, V; Shao, G; Tak, WY; Tanwandee, T; Walters, IB; Wang, JH; Wu, C; Yan, L; Yang, J; Yu, X | 1 |
| Benbrook, DM; Goodfellow, PJ; Hoffman, JS; Jeske, Y; Lankes, HA; Lee, PS; Leslie, KK; Mannel, RS; McMeekin, DS; Pollock, PM; Powell, MA; Sill, MW; Spillman, MA | 1 |
| Badawy, S; Desai, D; Kestur, U; Lin, J; Pandey, P | 1 |
| Badawy, S; Bindra, D; Macias, K; Narang, AS; Pandey, P; Sheverev, VA; Stepaniuk, V; Stevens, T; Varia, S; Wolf, A | 1 |
| Ang, C | 1 |
| Badawy, S; Crison, J; Derbin, G; Galella, M; Huang, Y; Narang, AS; Patel, D; Raghavan, K; Ramirez, A; Rinaldi, FA; Vig, B; Vincent, M; Xu, Y; Yamniuk, A; Ye, Q | 1 |
| Kalyan, A; Kulik, L; Nimeiri, H | 1 |
| Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L | 1 |
| Heng, JYY; Hussain, MA; Narang, AS; Olusanmi, D; Shah, UV; Tobyn, MJ; Wang, Z | 1 |
| Khochenkov, DA; Peretolchina, NM; Ryabaya, OO; Solomko, ES; Stepanova, EV | 1 |
| Badawy, SI; LaMarche, KR; Lin, J; Narang, AS; Shah, PA; Stevens, T; Subramanian, GA; Varia, SA | 1 |
| Badawy, S; Gao, Z; Macias, K; Narang, AS; Paruchuri, S; Stevens, T | 1 |
| Ba-Sang, DZ; Li, MS; Long, ZW; Qiu, J; Teng, H; Zhao, XP | 1 |
| Assenat, E; Boige, V; Chang, C; Decaens, T; Kang, YK; Kudo, M; Lencioni, R; Lim, HY; Llovet, JM; Montal, R; Park, JW; Raoul, JL; Ríos, J; Torres, F; Walters, I | 1 |
| Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS | 1 |
| Hu, Y; Li, X; Lou, L; Tu, J; Wan, J; Wu, S; Wu, Z | 1 |
| Chen, E; Dobrovic, A; Espin-Garcia, O; Jonker, DJ; Kubo, M; Latifovic, L; Liu, G; Morgen, E; Mushiroda, T; O'Callaghan, CJ; Price, TJ; Ratain, MJ; Shapiro, J; Shepshelovich, D; Siu, LL; Townsend, AR; Tu, D; Xu, W | 1 |
| Jonker, DJ; Karapetis, C; Liu, G; O'Callaghan, CJ; Price, TJ; Shapiro, JD; Simes, J; Siu, LL; Tebbutt, NC; Tu, D; Wells, JC | 1 |
| Baglioni, M; Bolondi, L; D'Errico, A; Giannone, FA; Giovannini, C; Gramantieri, L; Salzano, AM; Scaloni, A; Svegliati Baroni, G; Vasuri, F; Vitale, M; Zambrano, N | 1 |
| Yang, X; Yi, C; Zhang, C; Zhu, H | 1 |
| Chen, J; Ding, D; Gu, J; Li, L; Liu, D; Liu, X; Qin, B; Sang, A; Shi, Y; Tu, Y; Wu, W; Zhu, M | 1 |
| Abdul Razak, AR; Awada, A; Baurain, JF; Bedard, PL; Brockstein, B; D'Adamo, D; de Vos-Geelen, JMPGM; DeGreve, J; DeJonge, M; Dickson, M; Evans, TRJ; Geary, D; Janisch, L; Jassem, J; Jones, RL; Kaye, SB; Khayat, D; Kristeleit, R; Maki, R; Medioni, J; O'Dwyer, PJ; Obel, J; Ratain, MJ; Rudin, C; Sawyer, M; Schwartz, G; Siu, LL; Undevia, S; Vitfell-Rasmussen, J; Walters, I | 1 |
| Ceckova, M; Chen, S; Guo, L; Hofman, J; Kammerer, S; Küpper, JH; Sorf, A; Staud, F; Sucha, S; Vagiannis, D | 1 |
| Chen, X; Li, L; Liu, S; Wan, Y; Wu, W; Yao, X; Zhang, J | 1 |
| Cao, Y; Chen, C; Chen, J; Chen, L; Dang, Y; Fei, Y; Gao, J; Ge, B; Gu, J; Liu, H; Lu, H; Ma, M; Ren, Y; Su, C; Su, H; Wang, F; Wu, C; Wu, J; Wu, X; Xi, JJ; Xie, H; Xu, J; Xu, L; Xu, Z; Yin, S; Zhang, H; Zheng, M | 1 |
10 review(s) available for alanine and brivanib
| Article | Year |
|---|---|
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Topics: Alanine; Clinical Trials as Topic; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Brivanib alaninate for cancer.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Topics: Alanine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Triazines; Vascular Endothelial Growth Factor A | 2011 |
Brivanib: a review of development.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Treatment Outcome; Triazines | 2012 |
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
Topics: Alanine; Antineoplastic Agents; Benzimidazoles; Carcinoma, Squamous Cell; Gene Amplification; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Quinolones; Receptors, Fibroblast Growth Factor; Signal Transduction; Triazines | 2013 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; PubMed; Pyridines; Retreatment; Salvage Therapy; Treatment Failure; Triazines | 2014 |
Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Topics: Alanine; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Chromosome Aberrations; Drug Discovery; Gene Fusion; Humans; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor; Signal Transduction; Triazines | 2015 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
Topics: Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Drug Therapy; Humans; Neoplasm Metastasis; Panitumumab; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome; Triazines | 2016 |
Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Topics: Aged; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Triazines | 2018 |
18 trial(s) available for alanine and brivanib
| Article | Year |
|---|---|
Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Aged; Alanine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Pyrroles; Triazines | 2010 |
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Triazines | 2011 |
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrroles; Treatment Outcome; Triazines; Tumor Burden | 2011 |
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Cross-Over Studies; Female; Food; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Triazines | 2011 |
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Topics: Adult; Aged; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Therapy, Combination; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Tissue Distribution; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Topics: Administration, Oral; Adult; Alanine; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Fibroblast Growth Factors; Half-Life; Humans; Injections, Intravenous; Intestines; Liver; Male; Metabolic Detoxication, Phase I; Midazolam; Middle Aged; Patient Dropouts; Prodrugs; Receptors, Vascular Endothelial Growth Factor; Triazines | 2012 |
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alanine; alpha-Fetoproteins; Appetite; Carcinoma, Hepatocellular; Collagen Type IV; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Nausea; Treatment Outcome; Triazines; Young Adult | 2012 |
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
Topics: Adult; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genes, ras; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Treatment Failure; Triazines | 2013 |
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
Topics: Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Hepatic Insufficiency; Humans; Liver; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Patient Dropouts; Prodrugs; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Triazines | 2013 |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Topics: Alanine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diarrhea; Fatigue; Genes, ras; Humans; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Triazines | 2014 |
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Receptors, Fibroblast Growth Factor; Treatment Failure; Triazines; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Receptor, Fibroblast Growth Factor, Type 2; Triazines; Vascular Endothelial Growth Factor A | 2014 |
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prognosis; Triazines; Young Adult | 2017 |
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Triazines; Uterine Cervical Neoplasms | 2017 |
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Topics: Aged; Alanine; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Polymorphism, Genetic; Receptors, IgG; Survival Analysis; Triazines | 2018 |
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Topics: Aged; Alanine; Antineoplastic Agents; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Prognosis; Survival Rate; Triazines; Withholding Treatment | 2019 |
43 other study(ies) available for alanine and brivanib
| Article | Year |
|---|---|
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Prodrugs; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
Topics: Alanine; Animals; Biomarkers, Tumor; Cell Line, Tumor; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Receptor, Fibroblast Growth Factor, Type 1; RNA, Messenger; Transcription, Genetic; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Carcinoma; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Intestines; Liver; Lung Neoplasms; Mice; Microsomes; Molecular Structure; Prodrugs; Protein Kinase Inhibitors; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Solubility; Stereoisomerism; Triazines; Vascular Endothelial Growth Factor Receptor-2; Water; Xenograft Model Antitumor Assays | 2008 |
Direct and indirect separations of five isomers of Brivanib Alaninate using chiral high-performance liquid chromatography.
Topics: Alanine; Chromatography, High Pressure Liquid; Polysaccharides; Stereoisomerism; Temperature; Triazines | 2008 |
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Topics: Alanine; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Male; Mice; Models, Chemical; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Triazines | 2008 |
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Topics: Administration, Oral; Alanine; Animals; Antineoplastic Agents; Biological Availability; Brain; Caco-2 Cells; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Injections, Intravenous; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Pyrroles; Rats; Solubility; Tissue Distribution; Triazines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Topics: Alanine; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Gene Amplification; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Fibroblast Growth Factor, Type 1; RNA, Messenger; Signal Transduction; Triazines | 2010 |
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Topics: Alanine; Animals; Antigens, CD34; Cell Line, Tumor; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Laminin; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Proteoglycans; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Time Factors; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Random Allocation; Receptor, Fibroblast Growth Factor, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transplantation, Heterologous; Triazines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Topics: Administration, Oral; Alanine; Animals; Antineoplastic Agents; Bile; Biotransformation; Feces; Humans; Macaca fascicularis; Male; Neoplasms; Radioligand Assay; Rats; Rats, Sprague-Dawley; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Topics: Alanine; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Knockout; Mice, Transgenic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Fibroblast Growth Factor; Sorafenib; Treatment Outcome; Triazines; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Overcoming antiangiogenic resistance.
Topics: Alanine; Animals; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Triazines | 2011 |
Malignant peripheral nerve sheath tumour presenting as a pneumothorax.
Topics: Adult; Alanine; Antineoplastic Agents; Fatal Outcome; Humans; Male; Nerve Sheath Neoplasms; Peripheral Nervous System Neoplasms; Pneumothorax; Pyrroles; Radiography, Thoracic; Triazines | 2011 |
Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib.
Topics: Alanine; Biotransformation; Cytochrome P-450 Enzyme System; Cytosol; Humans; Oxidation-Reduction; Sulfotransferases; Triazines | 2012 |
Acid-catalyzed hydrolysis of BMS-582664: degradation product identification and mechanism elucidation.
Topics: Acids; Alanine; Antineoplastic Agents; Catalysis; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Hydrogen-Ion Concentration; Hydrolysis; Oxygen Isotopes; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Technology, Pharmaceutical; Triazines; Water | 2012 |
Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
Topics: Alanine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Triazines | 2012 |
Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Buffers; Calorimetry; Carboxymethylcellulose Sodium; Drug Interactions; Excipients; Hydrogen-Ion Concentration; Macaca fascicularis; Male; Models, Biological; Tablets; Triazines | 2012 |
Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation.
Topics: Alanine; Drug Compounding; Isoxazoles; Particle Size; Porosity; Powders; Pyrazoles; Quality Control; Solubility; Tablets; Technology, Pharmaceutical; Triazines; Water | 2012 |
Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
Topics: Administration, Oral; Adolescent; Adult; Alanine; Animals; Area Under Curve; Cytosol; Female; Humans; Ketones; Macaca fascicularis; Male; Microsomes, Liver; Middle Aged; NADP; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Mice; Mice, Nude; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Rabeprazole; Random Allocation; Sunitinib; Triazines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Triazines | 2013 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A | 2014 |
Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using ¹H HR-MAS spectroscopy and histopathology.
Topics: Alanine; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Immunoenzyme Techniques; Liver Neoplasms; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred BALB C; Triazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
Topics: Alanine; Animals; Cell Proliferation; Cells, Cultured; Hepatic Stellate Cells; Hypertension, Portal; Liver Cirrhosis; Male; Molecular Targeted Therapy; Rats; Rats, Sprague-Dawley; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Triazines | 2014 |
Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
Topics: Alanine; Animals; Carbon Tetrachloride Poisoning; Cell Line; Cell Proliferation; Cell Survival; Collagen Type I; Collagen Type I, alpha 1 Chain; Fibroblast Growth Factors; Hepatic Stellate Cells; Humans; Immunohistochemistry; Liver Cirrhosis; Liver Neoplasms; Mice; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Triazines; Vascular Endothelial Growth Factor A | 2014 |
Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.
Topics: Alanine; Angiogenesis Inhibitors; Chemistry, Pharmaceutical; Computer Simulation; Drug Stability; Humidity; Hydrolysis; Kinetics; Models, Chemical; Prodrugs; Quality Control; Solubility; Tablets; Technology, Pharmaceutical; Temperature; Triazines; Water | 2014 |
Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Topics: Administration, Oral; Alanine; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Contrast Media; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Triazines; Tumor Burden | 2014 |
Controlling the chemical stability of a moisture-sensitive drug product through monitoring and identification of coating process microenvironment.
Topics: Alanine; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Humidity; Hydrolysis; Tablets; Temperature; Thermodynamics; Triazines; Water | 2014 |
Real-time assessment of granule densification in high shear wet granulation and application to scale-up of a placebo and a brivanib alaninate formulation.
Topics: Administration, Oral; Alanine; Carboxymethylcellulose Sodium; Cellulose; Chemistry, Pharmaceutical; Equipment Design; Excipients; Kinetics; Lactose; Models, Chemical; Models, Statistical; Particle Size; Placebos; Porosity; Powders; Quality Control; Solubility; Tablets; Technology, Pharmaceutical; Triazines; Water | 2015 |
Role of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.
Topics: Administration, Oral; Alanine; Buffers; Calorimetry; Chemistry, Pharmaceutical; Colloids; Computer Simulation; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Magnetic Resonance Spectroscopy; Models, Molecular; Particle Size; Solubility; Surface Tension; Triazines | 2015 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines | 2015 |
Effect of milling temperatures on surface area, surface energy and cohesion of pharmaceutical powders.
Topics: Alanine; Calorimetry, Differential Scanning; Crystallization; Particle Size; Surface Properties; Technology, Pharmaceutical; Temperature; Triazines | 2015 |
Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2.
Topics: Alanine; Allosteric Regulation; Angiogenesis Inhibitors; Animals; Benzoates; Bevacizumab; Cell Line; Collagen; Drug Combinations; Endothelial Cells; Female; Fibroblast Growth Factor 2; Heparin; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Proteoglycans; Random Allocation; Receptor, Fibroblast Growth Factor, Type 2; Sulfonamides; Triazines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
Topics: Adhesiveness; Alanine; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Drug Liberation; Drug Packaging; Drug Stability; Particle Size; Quality Control; Solubility; Spectroscopy, Near-Infrared; Tablets, Enteric-Coated; Technology, Pharmaceutical; Triazines | 2016 |
Application of In-line Focused Beam Reflectance Measurement to Brivanib Alaninate Wet Granulation Process to Enable Scale-up and Attribute-based Monitoring and Control Strategies.
Topics: Alanine; Drug Compounding; Excipients; Lasers; Particle Size; Powders; Triazines; Water | 2017 |
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.
Topics: Age Factors; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Triazines | 2019 |
Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
Topics: Alanine; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; MCF-7 Cells; Molecular Targeted Therapy; Proteomics; Rats; Rats, Wistar; Receptor, Notch3; RNA, Small Interfering; Triazines; Two-Dimensional Difference Gel Electrophoresis | 2019 |
Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
Topics: Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Retreatment; Sorafenib; Treatment Failure; Triazines | 2019 |
Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Choroidal Neovascularization; Disease Models, Animal; Endothelial Cells; Lasers; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Triazines; Wet Macular Degeneration; Zebrafish | 2020 |
Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Topics: Alanine; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biotransformation; Cell Line; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Madin Darby Canine Kidney Cells; Neoplasm Proteins; Triazines | 2019 |
Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway.
Topics: Alanine; AMP-Activated Protein Kinases; Animals; Antiviral Agents; Cells, Cultured; Dengue; Dengue Virus; Disease Models, Animal; Endothelial Cells; Host-Pathogen Interactions; Humans; Mice; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Signal Transduction; Triazines; Vascular Endothelial Growth Factor Receptor-2; Virus Replication | 2021 |
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity.
Topics: Alanine; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cisplatin; High-Throughput Screening Assays; Humans; Interferons; Neoplasms; Nucleotidyltransferases; Triazines; Tumor Cells, Cultured | 2023 |